Mental disorders and thrombotic risk

Seminars in Thrombosis and Hemostasis

Volumn 39, Issue 8, 2013, Pages 943-949

  Hoirisch Clapauch, Silvia ^a   Nardi, Antonio E ^b   Gris, Jean Christophe ^c   Brenner, Benjamin ^d  

^a Servidores Do Estado Hospital   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c NÎMES UNIVERSITY HOSPITAL   (France)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

depression; mental stress; PAI 1; plasminogen activator; psychosis; schizophrenia; venous thromboembolism

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; ESTROGEN; GESTAGEN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE; SEROTONIN; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA;

ANXIETY; ARTICLE; BLOOD BRAIN BARRIER; CHRONIC STRESS; DEEP VEIN THROMBOSIS; DEPRESSION; EATING DISORDER; ESTROGEN BLOOD LEVEL; FOOD CRAVING; HUMAN; INCREASED APPETITE; MENTAL DISEASE; MENTAL STRESS; METABOLIC SYNDROME X; OVARY POLYCYSTIC DISEASE; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PSYCHOSIS; RISK; THROMBOEMBOLISM; THROMBOSIS PREVENTION; THROMBOTIC RISK; VENOUS THROMBOEMBOLISM;

HUMANS; MENTAL DISORDERS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK ASSESSMENT; RISK FACTORS; THROMBOEMBOLISM; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84887018014     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0033-1357486     Document Type: Article

References (72)

1. Thrall G., Lane D., Carroll D., Lip G. Y. A systematic review of the effects of acute psychological stress and physical activity on haemorheology, coagulation, fibrinolysis and platelet reactivity: Implications for the pathogenesis of acute coronary syndromes. Thromb Res: 2007; 120 6 819 847 (Pubitemid 47418227)
2. Austin A. W., Patterson S. M., von Känel R. Hemoconcentration and hemostasis during acute stress: interacting and independent effects. Ann Behav Med: 2011; 42 2 153 173
3. Austin A. W., Wirtz P. H., Patterson S. M., Stutz M., von Känel R. Stress-induced alterations in coagulation: assessment of a new hemoconcentration correction technique. Psychosom Med: 2012; 74 3 288 295
4. Strike P. C., Magid K., Whitehead D. L., Brydon L., Bhattacharyya M. R., Steptoe A. Pathophysiological processes underlying emotional triggering of acute cardiac events. Proc Natl Acad Sci U S A: 2006; 103 11 4322 4327
5. Schaefer U., Machida T., Vorlova S., Strickland S., Levi R. The plasminogen activator system modulates sympathetic nerve function. J Exp Med: 2006; 203 9 2191 2200 (Pubitemid 44352239)
6. Geiser F., Meier C., Wegener I., et al. Association between anxiety and factors of coagulation and fibrinolysis. Psychother Psychosom: 2008; 77 6 377 383
7. Räikkönen K., Lassila R., Keltikangas-Järvinen L., Hautanen A. Association of chronic stress with plasminogen activator inhibitor-1 in healthy middle-aged men. Arterioscler Thromb Vasc Biol: 1996; 16 3 363 367 (Pubitemid 26084310)
8. Robicsek O., Makhoul B., Klein E., Brenner B., Sarig G. Hypercoagulation in chronic post-traumatic stress disorder. Isr Med Assoc J: 2011; 13 9 548 552
9. Jönsson A. K., Spigset O., Hägg S. Venous thromboembolism in recipients of antipsychotics: incidence, mechanisms and management. CNS Drugs: 2012; 26 8 649 662
10. Austin A. W., Wissmann T., von Kanel R. Stress and hemostasis: an update. Semin Thromb Hemost: 2013; 39 8
11. Dietrich-Muszalska A., Rabe-Jablonska J., Nowak P., Kontek B. The first- and second-generation antipsychotic drugs affect ADP-induced platelet aggregation. World J Biol Psychiatry: 2010; 11 2 Pt 2 268 275
12. Halacheva K., Dimova S., Tolev T., Dimov D., Nikolova M. Elevated anticardiolipin antibodies in schizophrenic patients before and during neuroleptic medication. Psychiatry Res: 2009; 169 1 51 55
13. Masopust J., Malý R., Andrýs C., Vališ M., Bažant J., Hosák L. Markers of thrombogenesis are activated in unmedicated patients with acute psychosis: a matched case control study. BMC Psychiatry: 2011; 11 2
14. Guest P. C., Wang L., Harris L. W., et al. Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naïve schizophrenia patients. Mol Psychiatry: 2010; 15 2 118 119
15. Allenet B., Schmidlin S., Genty C., Bosson J. L. Antipsychotic drugs and risk of pulmonary embolism. Pharmacoepidemiol Drug Saf: 2012; 21 1 42 48
16. Skrzypiec A. E., Buczko W., Pawlak R. Tissue plasminogen activator in the amygdala: a new role for an old protease. J Physiol Pharmacol: 2008; 59 08 135 146
17. Wright J. W., Harding J. W. Contributions of matrix metalloproteinases to neural plasticity, habituation, associative learning and drug addiction. Neural Plast: 2009; 2009 579382
18. Maiya R., Zhou Y., Norris E. H., Kreek M. J., Strickland S. Tissue plasminogen activator modulates the cellular and behavioral response to cocaine. Proc Natl Acad Sci U S A: 2009; 106 6 1983 1988
19. Yamada K., Nagai T., Nabeshima T. Drug dependence, synaptic plasticity, and tissue plasminogen activator. J Pharmacol Sci: 2005; 97 2 157 161 (Pubitemid 40410252)
20. Nagai T., Ito M., Nakamichi N., et al. The rewards of nicotine: regulation by tissue plasminogen activator-plasmin system through protease activated receptor-1. J Neurosci: 2006; 26 47 12374 12383 (Pubitemid 44808404)
21. Madani R., Hulo S., Toni N., et al. Enhanced hippocampal long-term potentiation and learning by increased neuronal expression of tissue-type plasminogen activator in transgenic mice. EMBO J: 1999; 18 11 3007 3012 (Pubitemid 29255609)
22. Baron A., Hommet Y., Cassé F., Vivien D. Tissue-type plasminogen activator induces plasmin-dependent proteolysis of intracellular neuronal nitric oxide synthase. Biol Cell: 2010; 102 10 539 547
23. Liot G., Roussel B. D., Lebeurrier N., et al. Tissue-type plasminogen activator rescues neurones from serum deprivation-induced apoptosis through a mechanism independent of its proteolytic activity. J Neurochem: 2006; 98 5 1458 1464 (Pubitemid 44200437)
24. Lynch M. A. Long-term potentiation and memory. Physiol Rev: 2004; 84 1 87 136 (Pubitemid 38049877)
25. Doring T. M., Kubo T. T., Cruz L. C. Jr., et al. Evaluation of hippocampal volume based on MR imaging in patients with bipolar affective disorder applying manual and automatic segmentation techniques. J Magn Reson Imaging: 2011; 33 3 565 572
26. Velakoulis D., Wood S. J., Wong M. T., et al. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry: 2006; 63 2 139 149 (Pubitemid 43213875)
27. Chrapko W. E., Jurasz P., Radomski M. W., Lara N., Archer S. L., Le Mellédo J. M. Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder. Biol Psychiatry: 2004; 56 2 129 134 (Pubitemid 38844788)
28. Enga K. F., Brækkan S. K., Hansen-Krone I. J., Hansen J. B. Emotional states and future risk of venous thromboembolism: the Tromso Study. Thromb Haemost: 2012; 107 3 485 493
29. Vikenes K., Farstad M., Nordrehaug J. E. Serotonin is associated with coronary artery disease and cardiac events. Circulation: 1999; 100 5 483 489 (Pubitemid 29360156)
30. Lespérance F., Frasure-Smith N., Koszycki D., et al. CREATE Investigators Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA: 2007; 297 4 367 379 (Pubitemid 46155798)
31. Taylor C. B., Youngblood M. E., Catellier D., et al. ENRICHD Investigators Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry: 2005; 62 7 792 798 (Pubitemid 41002762)
32. Galan A. M., Lopez-Vilchez I., Diaz-Ricart M., et al. Serotonergic mechanisms enhance platelet-mediated thrombogenicity. Thromb Haemost: 2009; 102 3 511 519
33. Berger J. S., Becker R. C., Kuhn C., Helms M. J., Ortel T. L., Williams R. Hyperreactive platelet phenotypes: relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation. Thromb Haemost: 2013; 109 1 85 92
34. McEwen B. S. Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. Metabolism: 2005; 54 5 01 20 23 (Pubitemid 40546018)
35. Matthews K. A., Schott L. L., Bromberger J., Cyranowski J., Everson-Rose S. A., Sowers M. F. Associations between depressive symptoms and inflammatory/hemostatic markers in women during the menopausal transition. Psychosom Med: 2007; 69 2 124 130 (Pubitemid 46667978)
36. Eskandari F., Mistry S., Martinez P. E., et al. POWER (Premenopausal, Odteopenia/Osteoporosis, Women, Alendronate, Depression) Study Group. Younger, premenopausal women with major depressive disorder have more abdominal fat and increased serum levels of prothrombotic factors: implications for greater cardiovascular risk. Metabolism: 2005; 54 7 918 924 (Pubitemid 40827208)
37. Greggersen W., Rudolf S., Fassbinder E., et al. Major depression, borderline personality disorder, and visceral fat content in women. Eur Arch Psychiatry Clin Neurosci: 2011; 261 8 551 557
38. Hollinrake E., Abreu A., Maifeld M., Van Voorhis B. J., Dokras A. Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertil Steril: 2007; 87 6 1369 1376 (Pubitemid 46829130)
39. Cibula D., Cífková R., Fanta M., Poledne R., Zivny J., Skibová J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod: 2000; 15 4 785 789 (Pubitemid 30192723)
40. Huotari A., Lehto S. M., Niskanen L., et al. Increased serum PAI-1 levels in subjects with metabolic syndrome and long-term adverse mental symptoms: a population-based study. Cardiovasc Psychiatry Neurol: 2010;;doi:10.1155/2010/ 501349
41. Cahill M. A. Progesterone receptor membrane component 1: an integrative review. J Steroid Biochem Mol Biol: 2007; 105 1-5 16 36 (Pubitemid 47211947)
42. Fiumelli H., Jabaudon D., Magistretti P. J., Martin J. L. BDNF stimulates expression, activity and release of tissue-type plasminogen activator in mouse cortical neurons. Eur J Neurosci: 1999; 11 5 1639 1646
43. Su C., Cunningham R. L., Rybalchenko N., Singh M. Progesterone increases the release of brain-derived neurotrophic factor from glia via progesterone receptor membrane component 1 (Pgrmc1)-dependent ERK5 signaling. Endocrinology: 2012; 153 9 4389 4400
44. He G., Pedersen S. B., Bruun J. M., Richelsen B. Regulation of plasminogen activator inhibitor-1 in human adipose tissue: interaction between cytokines, cortisol and estrogen. Horm Metab Res: 2000; 32 11-12 515 520 (Pubitemid 32176080)
45. Peluso J. J., Yuan A., Liu X., Lodde V. Plasminogen activator inhibitor 1 RNA-binding protein interacts with progesterone receptor membrane component 1 to regulate progesterone's ability to maintain the viability of spontaneously immortalized granulosa cells and rat granulosa cells. Biol Reprod: 2013; 88 1 20
46. North American Menopause Society Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause: 2010; 17 2 242 255
47. Brinton R. D., Thompson R. F., Foy M. R., et al. Progesterone receptors: form and function in brain. Front Neuroendocrinol: 2008; 29 2 313 339
48. Mortola J. F. Premenstrual syndrome. In: Goldman M. B., Hatch M., eds. Women and Health. San Diego, CA Academic Press: 2000; 114 125
49. Sjöberg N. O. Dysmenorrhea and uterine neurotransmitters. Acta Obstet Gynecol Scand Suppl: 1979; 87 57 59 (Pubitemid 9174414)
50. Nisar N., Zehra N., Haider G., Munir A. A., Sohoo N. A. Frequency, intensity and impact of premenstrual syndrome in medical students. J Coll Physicians Surg Pak: 2008; 18 8 481 484
51. Vichnin M., Freeman E. W., Lin H., Hillman J., Bui S. Premenstrual syndrome (PMS) in adolescents: severity and impairment. J Pediatr Adolesc Gynecol: 2006; 19 6 397 402 (Pubitemid 44894959)
52. McColl B. K., Baldwin M. E., Roufail S., et al. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D. J Exp Med: 2003; 198 6 863 868 (Pubitemid 37152923)
53. Kim D. R., Czarkowski K. A., Epperson C. N. The relationship between bipolar disorder, seasonality, and premenstrual symptoms. Curr Psychiatry Rep: 2011; 13 6 500 503
54. Yen J. Y., Chang S. J., Ko C. H., et al. The high-sweet-fat food craving among women with premenstrual dysphoric disorder: emotional response, implicit attitude and rewards sensitivity. Psychoneuroendocrinology: 2010; 35 8 1203 1212
55. Erdman J. W. Jr, Balentine D., Arab L., et al. Flavonoids and heart health: proceedings of the ILSI North America Flavonoids Workshop, May 31-June 1, 2005, Washington, DC. J Nutr: 2007; 137 3 01 718S 737S (Pubitemid 46397511)
56. Zhao X., Gu Z., Attele A. S., Yuan C. S. Effects of quercetin on the release of endothelin, prostacyclin and tissue plasminogen activator from human endothelial cells in culture. J Ethnopharmacol: 1999; 67 3 279 285 (Pubitemid 29469737)
57. Shenouda S. M., Vita J. A. Effects of flavonoid-containing beverages and EGCG on endothelial function. J Am Coll Nutr: 2007; 26 4 366S 372S (Pubitemid 47579906)
58. Masho S. W., Adera T., South-Paul J. Obesity as a risk factor for premenstrual syndrome. J Psychosom Obstet Gynaecol: 2005; 26 1 33 39 (Pubitemid 40571282)
59. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand: 1999; 100 1 3 16 (Pubitemid 29309192)
60. Sartori C. R., Vieira A. S., Ferrari E. M., Langone F., Tongiorgi E., Parada C. A. The antidepressive effect of the physical exercise correlates with increased levels of mature BDNF, and proBDNF proteolytic cleavage-related genes, p11 and tPA. Neuroscience: 2011; 180 9 18
61. Kassam G., Le B. H., Choi K. S., et al. The p11 subunit of the annexin II tetramer plays a key role in the stimulation of t-PA-dependent plasminogen activation. Biochemistry: 1998; 37 48 16958 16966 (Pubitemid 28566773)
62. Maskall D. D., Lam R. W., Misri S., et al. Seasonality of symptoms in women with late luteal phase dysphoric disorder. Am J Psychiatry: 1997; 154 10 1436 1441 (Pubitemid 27415613)
63. Wittkowsky A. K. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med: 2003; 3 3 221 230 (Pubitemid 37280710)
64. Hoirisch-Clapauch S., Nardi A. E. Psychiatric remission with warfarin: Should psychosis be addressed as plasminogen activator imbalance? Med Hypotheses: 2013; 80 2 137 141
65. Walsh A. C. Prevention of senile and presenile dementia by bishydroxycoumarin (Dicumarol) therapy. J Am Geriatr Soc: 1969; 17 5 477 487
66. Bahi A., Dreyer J. L. Overexpression of plasminogen activators in the nucleus accumbens enhances cocaine-, amphetamine- and morphine-induced reward and behavioral sensitization. Genes Brain Behav: 2008; 7 2 244 256 (Pubitemid 351342201)
67. Esse K., Fossati-Bellani M., Traylor A., Martin-Schild S. Epidemic of illicit drug use, mechanisms of action/addiction and stroke as a health hazard. Brain Behav: 2011; 1 1 44 54
68. Patten S. B., Barbui C. Drug-induced depression: a systematic review to inform clinical practice. Psychother Psychosom: 2004; 73 4 207 215 (Pubitemid 38822722)
69. van Zonneveld A. J., Curriden S. A., Loskutoff D. J. Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter. Proc Natl Acad Sci U S A: 1988; 85 15 5525 5529
70. Baars J. W., de Boer J. P., Wagstaff J., et al. Interleukin-2 induces activation of coagulation and fibrinolysis: resemblance to the changes seen during experimental endotoxemia. Br J Haematol: 1992; 82 2 295 301
71. Cash J. D., Woodfield D. G., Allan A. G. Adrenergic mechanisms in the systemic plasminogen active response to adrenaline in man. Br J Haematol: 1970; 18 4 487 494
72. Tsai S. J., Hong C. J., Liou Y. J., Yu Y. W., Chen T. J. Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response. Pharmacogenet Genomics: 2008; 18 10 869 875